LH-RH analogues have come into use to suppress the synthesis of testosterone by the testes and to induce palliation in advanced prostate cancer. Twenty-one patients were treated with buserelin (Hoe 766), and 19 were evaluable. Stages of disease were D1-D2. Seventeen patients responded to treatment, 3 patients are still in partial response, and 16 underwent progression. The median time to progression was 12 months (range, 3–36), and the median follow-up time was 10 months (mean, 25.4; range, 5–48).
Get full access to this article
View all access options for this article.
References
1.
BorgmanV., NagelR., Al-AbadiH., Schmidt-GollwitzenM.: Treatment of prostatic cancer with LH-RH analogues. Prostate, 4: 553–568, 1983.
2.
EmmetJ.L., GreenL.F., PapantonioaA.: Endocrine studies in carcinoma of the prostate gland: 10 year survival studies. J. Urol., 83: 471–476, 1960.
3.
HugginsC., HodgesC.V.: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res., 1: 293–297, 1941.
4.
KaplanE.L., MeierP.: Nonparametric estimations from incomplete observations. J. Am. Stat. Ass., 53: 457–462, 1958.
5.
MurphyG.P., SlackN.H.: Response criteria for prostate in the USA National Prostatic Cancer Project. Prostate, 1: 375–382, 1980.
6.
PresantC., SolowayM.S., KliozeS.S.: Buserelin as primary therapy in advanced prostatic carcinoma. Cancer, 56: 2416–2419, 1985.
WenderothU.K., JacobiG.H.: Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate. A new approach to the classical concept. World J. Urol., 1: 40–48, 1983.
